Spero Therapeutics SG&A Expense (TTM) Trends

Spero Therapeutics Inc (SPRO)

1.29 0.00 (0.00%) USD | NASDAQ | Oct 04, 16:00

1.29 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Upgrade now.

Date	Value
June 30, 2024	23.59M
March 31, 2024	24.15M
December 31, 2023	25.55M
September 30, 2023	25.62M
June 30, 2023	26.54M
March 31, 2023	28.50M
December 31, 2022	36.48M
September 30, 2022	43.01M
June 30, 2022	47.53M
March 31, 2022	48.71M
December 31, 2021	41.70M
September 30, 2021	36.18M
June 30, 2021	30.34M
March 31, 2021	25.65M
December 31, 2020	21.44M

Date	Value
September 30, 2020	17.73M
June 30, 2020	16.55M
March 31, 2020	15.79M
December 31, 2019	15.59M
September 30, 2019	15.45M
June 30, 2019	14.45M
March 31, 2019	13.73M
December 31, 2018	12.89M
September 30, 2018	11.73M
June 30, 2018	12.25M
March 31, 2018	12.14M
December 31, 2017	10.84M
September 30, 2017	10.57M
June 30, 2017	8.824M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

15.59M

Minimum

Dec 2019

48.71M

Maximum

Mar 2022

28.98M

Average

25.65M

Median

Mar 2021

SG&A Expense (TTM) Benchmarks